Two‐year outcomes of tirabrutinib monotherapy in Waldenström’s macroglobulinemia-Reference-Cited by-同舟云学术

Two‐year outcomes of tirabrutinib monotherapy in Waldenström’s macroglobulinemia

Published:2022-04-06 Issue:6 Volume:113 Page:2085-2096
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Science

Author:

Sekiguchi Naohiro¹^ORCID,Rai Shinya²^ORCID,Munakata Wataru³,Suzuki Kenshi⁴,Handa Hiroshi⁵^ORCID,Shibayama Hirohiko⁶,Endo Tomoyuki⁷,Terui Yasuhito⁸,Iwaki Noriko⁹,Fukuhara Noriko¹⁰,Tatetsu Hiro¹¹,Iida Shinsuke¹²^ORCID,Ishikawa Takayuki¹³,Iguchi Daisuke¹⁴,Izutsu Koji³^ORCID

Affiliation:

1. Department of Hematology National Hospital Organization Disaster Medical Center Tachikawa Japan

2. Department of Hematology and Rheumatology Kindai University Faculty of Medicine Osakasayama Japan

3. Department of Hematology National Cancer Center Hospital Tokyo Japan

4. Department of Hematology Japanese Red Cross Medical Center Tokyo Japan

5. Department of Hematology Gunma University Graduate School of Medicine Maebashi Japan

6. Department of Hematology and Oncology Osaka University Graduate School of Medicine Suita Japan

7. Department of Hematology Hokkaido University Hospital Sapporo Japan

8. Department of Hematology Oncology The Cancer Institute Hospital of Japanese Foundation for Cancer Research Tokyo Japan

9. Department of Hematology Kanazawa University Hospital Kanazawa Japan

10. Department of Hematology and Rheumatology Tohoku University Graduate School of Medicine Sendai Japan

11. Department of Hematology, Rheumatology and Infectious disease Kumamoto University Hospital Kumamoto Japan

12. Department of Hematology and Oncology Nagoya City University Graduate School of Medical Sciences Nagoya Japan

13. Department of Hematology Kobe City Medical Center General Hospital Kobe Japan

14. Department of Clinical Development Ono Pharma USA, Inc. Cambridge Massachusetts USA

Funder

Ono Pharmaceutical

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.15344

Reference36 articles.

1. Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

2. Trends in Incidence and Mortality of Waldenström Macroglobulinemia: A Population-Based Study

3. Role of Bruton’s tyrosine kinase in B cells and malignancies

4. Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia

5. Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing BTK Inhibition in Waldenström Macroglobulinemia;Journal of the National Comprehensive Cancer Network;2024-05

2. How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia;Blood;2024-04-25

3. Bruton’s tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advances;Leukemia & Lymphoma;2024-04-10

4. New Means and Challenges in the Targeting of BTK;Clinical Cancer Research;2024-04-05

5. Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia;Current Hematologic Malignancy Reports;2024-03-27